TransCode Therapeutics In... (RNAZ)
Bid | 0.39 |
Market Cap | 9.34M |
Revenue (ttm) | 753.15K |
Net Income (ttm) | -14.93M |
EPS (ttm) | 5867.6 |
PE Ratio (ttm) | n/a |
Forward PE | -2.23 |
Analyst | Buy |
Ask | 0.4 |
Volume | 1,046,704 |
Avg. Volume (20D) | 7,354,883 |
Open | 0.38 |
Previous Close | 0.40 |
Day's Range | 0.37 - 0.40 |
52-Week Range | 0.34 - 66.33 |
Beta | 1.52 |
About RNAZ
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inh...
Analyst Forecast
According to 1 analyst ratings, the average rating for RNAZ stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 4898.75% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription

10 months ago · https://www.defenseworld.net
Q2 2024 EPS Estimates for TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Decreased by AnalystTransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) – Equities research analysts at HC Wainwright reduced their Q2 2024 earnings per share estimates for shares of TransCode Therapeuti...

1 year ago · proactiveinvestors.com
Transcode Therapeutic stock whipsaws lower after cut price placingTransCode Therapeutics (NASDAQ:RNAZ) stock has seen a wild 24 hours of trading as the Boston headquartered nano-cap drug discovery firm rocketed Monday, before coming back down to earth with an after-...

1 year ago · proactiveinvestors.com
TransCode Therapeutics stock skyrockets on positive brain cancer trial resultsTransCode Therapeutics (NASDAQ:RNAZ) shares took off after it announced positive results from a study of its lead drug candidate TTX-MC138 in mice models bearing human glioblastoma multiforme (GBM) tu...